Maximising clinical benefit with adequate patient management beyond the second line in mCRC

by Guillem Argiles, Dirk Arnold, Gerald Prager, Alberto F Sobrero, Eric Van Cutsem
Published 2019-04-01

and inhibition as treatment strategies in V600E metastatic colorectal cancer

by Javier Ros, Iosune Baraibar, Emilia Sardo, Nuria Mulet, Francesc Salvà, Guillem Argilés, Giulia Martini, Davide Ciardiello, José Luis Cuadra, Josep Tabernero, Elena Élez
Published 2021-02-01

Molecular subtypes and the evolution of treatment management in metastatic colorectal cancer

by Giulia Martini, Rodrigo Dienstmann, Javier Ros, Iosune Baraibar, Jose Luis Cuadra-Urteaga, Francesc Salva, Davide Ciardiello, Nuria Mulet, Guillem Argiles, Josep Tabernero, Elena Elez
Published 2020-07-01

Early Clinical Experience with Trifluridine/Tipiracil for Refractory Metastatic Colorectal Cancer: The ROS Study

by Pilar García-Alfonso, Andrés Muñoz, Jerónimo Jiménez-Castro, Paula Jiménez-Fonseca, Carles Pericay, Federico Longo-Muñoz, Carmen Reyna-Fortes, Guillem Argilés-Martínez, Beatriz González-Astorga, María José Gómez-Reina, Ana Ruiz-Casado, Nuria Rodríguez-Salas, Rafael López-López, Alberto Carmona-Bayonas, Verónica Conde-Herrero, Enrique Aranda, on behalf of the ROS Study Group
Published 2021-09-01

Impact of circulating tumor DNA mutant allele fraction on prognosis in RAS‐mutant metastatic colorectal cancer

by Elena Elez, Chiara Chianese, Enrique Sanz‐García, Erica Martinelli, Alba Noguerido, Francesco Mattia Mancuso, Ginevra Caratù, Judit Matito, Julieta Grasselli, Claudia Cardone, Riziero Esposito Abate, Giulia Martini, Cristina Santos, Teresa Macarulla, Guillem Argilés, Jaume Capdevila, Ariadna Garcia, Nuria Mulet, Evaristo Maiello, Nicola Normanno, Frederick Jones, Josep Tabernero, Fortunato Ciardello, Ramon Salazar, Ana Vivancos
Published 2019-09-01